Gilgamesh Pharmaceuticals

BREAKING NEWS - We are excited to announce a new collaboration and option-to-license agreement with AbbVie, aimed at developing novel transformative therapies for psychiatric disorders. Learn more: https://lnkd.in/epvaDCqC

Excited to share that Gilgamesh has been named one of the Fierce Biotech 15! It's an honor to be recognized among the top innovators in the biotech industry. We look forward to continuing to progress our breakthrough treatments for psychiatric patients in need. https://lnkd.in/eXVdVv4z

Gilgamesh Announces Initiation of Phase 2a Trial of GM-1020 in Major Depressive Disorder - Patient dosing has been initiated with GM-1020, a novel oral NMDA receptor antagonist - Initial results of the Phase 2a trial anticipated to be available in the 2nd half of 2024 Full Press Release: https://lnkd.in/ezkK2Zwv

Gilgamesh Announces Initiation of Phase 2a Trial of GM-1020 in Major Depressive Disorder - Patient dosing has been initiated with GM-1020, a novel oral NMDA receptor antagonist - Initial results of the Phase 2a trial anticipated to be available in the 2nd half of 2024 Full Press Release: https://lnkd.in/ezkK2Zwv

We're #hiring a new Associate Director/Director of CMC, Drug Substance Development in United States. Apply today or share this post with your network.

“What is the problem with ibogaine? It has cardiac toxicity” - Dr. Nora Volkow (Director of National Institute of Drug Abuse - NIDA) “Volkow’s agency is already funding research into that question, awarding a $14M grant to Gilgamesh Pharma to develop an ibogaine analog that says it could bring the same benefits without the associated cardiovascular risk” Via STAT, Lev Facher https://lnkd.in/edEgeWXt

Gilgamesh is proud to announce that we have received a $14M Grant from the NIH-NIDA to develop our novel cardiac-safe ibogaine analog for the treatment of Opioid Use Disorder. As summarized in a recent New York Times article (Powerful Psychedelic Gains Renewed Attention as a Treatment for Opioid Addiction), ibogaine, a plant-derived psychoactive compound, has accumulated data from trials and case reports that point to its robust efficacy as a treatment for substance use disorders. However, the development of ibogaine as a pharmaceutical has long been hindered by its significant cardiovascular toxicity. This grant provides non-dilutive funding to support IND-enabling toxicology studies, GMP manufacturing, and Phase 1/1b clinical trials in healthy volunteers and opioid use disorder (OUD) patients for GM-3009. The planned clinical work will seek to confirm that GM-3009 eliminates the cardiovascular risks associated with ibogaine and demonstrate proof-of-concept efficacy in attenuating symptoms associated with OUD. Following completion of the funded development, GM-3009 will be ready to enter larger Phase 2 efficacy studies. https://lnkd.in/e7uuXU5P

Excited to announce Gilgamesh's first peer-reviewed publication for GM-1020, our best in class oral ketamine analog. In addition to uniquely high oral availability, it is designed to have reduced dissociative/sedative properties which can potentially make it suitable for at-home use. https://lnkd.in/eQJkFRRX

Excited to announce Gilgamesh's first peer-reviewed publication for GM-1020, our best in class oral ketamine analog. In addition to uniquely high oral availability, it is designed to have reduced dissociative/sedative properties which can potentially make it suitable for at-home use. https://lnkd.in/eQJkFRRX

We are thrilled to announce that our second molecule, GM-2505, has successfully completed, Ph1 clinical trials. As we move into Ph2 studies, we are one step closer to bringing another innovative treatment to patients indeed.